Positron emission tomographic imaging of cardiac sympathetic innervation using 6-[18F]fluorodopamine: initial findings in humans
DS Goldstein,
G Eisenhofer,
BB Dunn,
I Armando,
J Lenders,
E Grossman,
C Holmes,
KL Kirk,
S Bacharach,
R Adams,
et al.
Clinical Neuroscience Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
OBJECTIVES. This study evaluated the safety, efficacy and validity of 6-[18F]fluorodopamine positron emission tomographic scanning of cardiac sympathetic innervation and function in humans. METHODS. Positron emission tomography (PET) scans, arterial blood and urine were obtained after a 3-min intravenous infusion of 6-[18F]fluorodopamine (1 to 4 mCi, 188 to 809 mCi/mmol) in healthy volunteers, with or without pretreatment with oral desipramine to inhibit neuronal uptake of catecholamines. RESULTS. 6-[18F]Fluorodopamine PET scanning visualized the left ventricular myocardium. Blood pressure increased slightly and transiently. The estimated absorbed radiation dose to the main target organ, the wall of the urinary bladder, was 0.8 to 1.0 rad/mCi of injected 6-[18F]fluorodopamine. By 24 h after the injection, the main 6F-compound in urine was 6F-vanillymandelic acid, a metabolite of 6F-norepinephrine. Desipramine attenuated accumulation of myocardial 6-[18F]fluorodopamine-derived radioactivity and plasma 6F-dihydroxyphenylacetic acid. CONCLUSIONS. 6-[18F]Fluorodopamine produces negligible hemodynamic effects and acceptable radiation exposure at doses that visualize the left ventricular myocardium. Sympathetic nerves take up 6-[18F]fluorodopamine, which is translocated from the axoplasm into storage vesicles, where is it beta-hydroxylated to the fluorinated analogue of the sympathetic neurotransmitter norepinephrine. Therefore, the basis for visualization of myocardium after 6-[18F]fluorodopamine injection in humans is radiolabeling by 6-[18F]fluorodopamine and 6-[18F]fluoronorepinephrine of vesicles in sympathetic terminals. 6-[18F]Fluorodopamine PET scanning provides a novel means for assessing sympathetic innervation and function noninvasively in the human heart.
This article has been cited by other articles:
|
|
|
|
 
D. S. GOLDSTEIN
Pioneer Award Address: Ignorance isn't biased: Comments on receiving the Pioneer Award
Cleveland Clinic Journal of Medicine,
April 1, 2009;
76(Suppl_2):
S31 - S36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. MOAK, D. S. GOLDSTEIN, B. A. ELDADAH, A. SALEEM, C. HOLMES, S. PECHNIK, and Y. SHARABI
Supine low-frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation*
Cleveland Clinic Journal of Medicine,
April 1, 2009;
76(Suppl_2):
S51 - S59.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Goldstein, R. Imrich, E. Peckham, C. Holmes, G. Lopez, C. Crews, J. Hardy, A. Singleton, and M. Hallett
Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation
Neurology,
October 16, 2007;
69(16):
1580 - 1584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hadi, C. C. Chen, M. Whatley, K. Pacak, and J. A. Carrasquillo
Brown Fat Imaging with 18F-6-Fluorodopamine PET/CT, 18F-FDG PET/CT, and 123I-MIBG SPECT: A Study of Patients Being Evaluated for Pheochromocytoma
J. Nucl. Med.,
July 1, 2007;
48(7):
1077 - 1083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Eldadah, K. Pacak, G. Eisenhofer, C. Holmes, I. J. Kopin, and D. S. Goldstein
Cardiac Uptake-1 Inhibition by High Circulating Norepinephrine Levels in Patients with Pheochromocytoma
Hypertension,
June 1, 2004;
43(6):
1227 - 1232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Singleton, K. Gwinn-Hardy, Y. Sharabi, S.-T. Li, C. Holmes, R. Dendi, J. Hardy, A. Singleton, A. Crawley, and D. S. Goldstein
Association between cardiac denervation and parkinsonism caused by {alpha}-synuclein gene triplication
Brain,
April 1, 2004;
127(4):
768 - 772.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-T. Li, C. Holmes, I. J. Kopin, and D. S. Goldstein
Aging-Related Changes in Cardiac Sympathetic Function in Humans, Assessed by 6-18F-Fluorodopamine PET Scanning
J. Nucl. Med.,
October 1, 2003;
44(10):
1599 - 1603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Goldstein, S.-T. Li, C. Holmes, and K. Bankiewicz
Sympathetic Innervation in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Primate Model of Parkinson's Disease
J. Pharmacol. Exp. Ther.,
September 1, 2003;
306(3):
855 - 860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Goldstein, D. Robertson, M. Esler, S. E. Straus, and G. Eisenhofer
Dysautonomias: Clinical Disorders of the Autonomic Nervous System
Ann Intern Med,
November 5, 2002;
137(9):
753 - 763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Goldstein, C. Holmes, S. M. Frank, R. Dendi, R. O. Cannon III, Y. Sharabi, M. D. Esler, and G. Eisenhofer
Cardiac Sympathetic Dysautonomia in Chronic Orthostatic Intolerance Syndromes
Circulation,
October 29, 2002;
106(18):
2358 - 2365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Goldstein, C. S. Holmes, R. Dendi, S. R. Bruce, and S.-T. Li
Orthostatic hypotension from sympathetic denervation in Parkinson's disease
Neurology,
April 23, 2002;
58(8):
1247 - 1255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Goldstein, C. Holmes, S.-T. Li, S. Bruce, L. V. Metman, and R. O. Cannon III
Cardiac Sympathetic Denervation in Parkinson Disease
Ann Intern Med,
September 5, 2000;
133(5):
338 - 347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-T. Li, C. J. Tack, L. Fananapazir, and D. S. Goldstein
Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy
J. Am. Coll. Cardiol.,
June 1, 2000;
35(7):
1867 - 1873.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Munch, N. T. B. Nguyen, S. Nekolla, S. Ziegler, O. Muzik, P. Chakraborty, D. M. Wieland, and M. Schwaiger
Evaluation of Sympathetic Nerve Terminals With [11C]Epinephrine and [11C]Hydroxyephedrine and Positron Emission Tomography
Circulation,
February 8, 2000;
101(5):
516 - 523.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
